{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:09:54Z","timestamp":1793531394209,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sodium-glucose co-transporter 2 (SGLT2) inhibitors are novel hypoglycemic agents which reduce reabsorption of glucose at the renal proximal tubule, resulting in significant glycosuria and increased risk of genital mycotic infections (GMI). These infections are typically not severe as reported in large systematic reviews and meta-analyses of the medications. These reviews have also demonstrated significant cardiovascular benefits through other mechanisms of action, making them attractive options for the management of Type 2 diabetes mellitus (T2DM). We present two cases with underlying abnormalities of the urogenital tract in which the GMI were complicated and necessitated cessation of the SGLT2 inhibitor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentations<\/jats:title>\n                <jats:p>Both cases are patients with T2DM on empagliflozin, an SGLT2 inhibitor. The first case is a 64 year old man with <jats:italic>Candida albicans<\/jats:italic> balanitis and candidemia who was found to have an obstructing renal calculus and prostatic abscess requiring operative management. The second case describes a 72 year old man with <jats:italic>Candida glabrata<\/jats:italic> candidemia who was found to have prostatomegaly, balanitis xerotica obliterans with significant urethral stricture and bladder diverticulae. His treatment was more complex due to fluconazole resistance and concerns about urinary tract penetration of other antifungals. Both patients recovered following prolonged courses of antifungal therapy and in both cases the SGLT2 inhibitor was ceased.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite their cardiovascular benefits, SGLT2 inhibitors can be associated with complicated fungal infections including candidemia and patients with anatomical abnormalities of the urogenital tract may be more susceptible to these infections as demonstrated in these cases. Clinicians should be aware of their mechanism of action and associated risk of infection and prior to prescription, assessment of urogenital anatomical abnormalities should be performed to identify patients who may be at risk of complicated infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-05982-3","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T08:02:22Z","timestamp":1616227342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8258-414X","authenticated-orcid":false,"given":"Caroline","family":"Bartolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Deborah","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Lanyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Orla","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Athan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"issue":"7","key":"5982_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/dom.12073","volume":"15","author":"T Heise","year":"2013","unstructured":"Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613\u201321. https:\/\/doi.org\/10.1111\/dom.12073.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"5982_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/dom.12244","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(5):457\u201366. https:\/\/doi.org\/10.1111\/dom.12244.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"5982_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783\u201394. https:\/\/doi.org\/10.1111\/dom.12670.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"5982_CR4","doi-asserted-by":"publisher","first-page":"e0166125","DOI":"10.1371\/journal.pone.0166125","volume":"11","author":"H Storgaard","year":"2016","unstructured":"Storgaard H, Gluud LL, Bennett C, Gr\u00f8ndahl MF, Christensen MB, Knop FK, Vilsb\u00f8ll T. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166125. https:\/\/doi.org\/10.1371\/journal.pone.0166125.","journal-title":"PLoS One"},{"issue":"15","key":"5982_CR5","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","volume":"319","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319(15):1580\u201391. https:\/\/doi.org\/10.1001\/jama.2018.3024.","journal-title":"JAMA"},{"issue":"24","key":"5982_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"6","key":"5982_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jdiacomp.2012.06.012","volume":"26","author":"I Hirji","year":"2012","unstructured":"Hirji I, Andersson SW, Guo Z, Hammar N, Gomez-Caminero A. Incidence of genital infection among patients with type 2 diabetes in the UK general practice research database. J Diabetes Complicat. 2012;26(6):501\u20135. https:\/\/doi.org\/10.1016\/j.jdiacomp.2012.06.012.","journal-title":"J Diabetes Complicat"},{"issue":"4","key":"5982_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"7","key":"5982_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1185\/03007995.2012.697053","volume":"28","author":"P Nyirjesy","year":"2012","unstructured":"Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173\u20138. https:\/\/doi.org\/10.1185\/03007995.2012.697053.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"5982_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter 2 inhibitors and the risk of severe urinary tract infection. Ann Intern Med. 2019;171(4):248\u201356. https:\/\/doi.org\/10.7326\/M18-3136.","journal-title":"Ann Intern Med"},{"issue":"4","key":"5982_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kaufmann CA, Andes DR, et al. Clinical guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1\u201350. https:\/\/doi.org\/10.1093\/cid\/civ933.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"5982_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/IPC.0b013e31816613f1","volume":"16","author":"S Gupta","year":"2008","unstructured":"Gupta S, Liu-Young G, Mahnensmith R, Topal JE. Prostatic abscess with Candida glabrata treated with Micafungin. Infect Dis Clin Pract. 2008;16(6):387\u20139. https:\/\/doi.org\/10.1097\/IPC.0b013e31816613f1.","journal-title":"Infect Dis Clin Pract"},{"issue":"1","key":"5982_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/CMR.00046-13","volume":"27","author":"T Felton","year":"2014","unstructured":"Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27(1):68\u201388. https:\/\/doi.org\/10.1128\/CMR.00046-13.","journal-title":"Clin Microbiol Rev"},{"issue":"suppl 6","key":"5982_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/cid\/cir112","volume":"52","author":"JF Fisher","year":"2011","unstructured":"Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections \u2013 treatment. Clin Infect Dis. 2011;52(suppl 6):457\u201366.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"5982_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1128\/AAC.33.4.467","volume":"33","author":"TJ Walsh","year":"1989","unstructured":"Walsh TJ, Foulds G, Pizzo PA. Pharmacokinetics and tissue penetration of fluconazole in rabbits. Antimicrob Agents Chemother. 1989;33(4):467\u20139. https:\/\/doi.org\/10.1128\/AAC.33.4.467.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"5982_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1128\/CMR.19.2.435-447.2006","volume":"19","author":"MA Pfaller","year":"2006","unstructured":"Pfaller MA, Diekama DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19(2):435\u201347. https:\/\/doi.org\/10.1128\/CMR.19.2.435-447.2006.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"5982_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijantimicag.2016.05.010","volume":"48","author":"S Grau","year":"2016","unstructured":"Grau S, Luque S, Echeverria-Esnal D, et al. Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp. Int J Antimicrob Agents. 2016;48(2):212\u20134. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.05.010.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"5982_CR18","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/cid\/cix033","volume":"64","author":"G Cuervo","year":"2017","unstructured":"Cuervo G, Garcia-Vidal C, Puig-Asensio M, et al. Echinocandins compared to fluconazole for Candidemia of a urinary tract source: a propensity score analysis. Clin Infect Dis. 2017;64(10):1374\u20139.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05982-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05982-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05982-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T08:02:36Z","timestamp":1616227356000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05982-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5982"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05982-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,20]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Both patients have provided written consent for publication and this can be provided if requested by the editors<b>.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}